MENLO PARK, Calif., Oct. 26, 2017 -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company, today announced that it has retained Cowen to assist in evaluating possible strategic transactions. The process is aimed at identifying opportunities to diversify the Versartis pipeline, including through potential strategic combinations, in order to leverage the company’s expertise and resources and create value for shareholders.
No assurances can be made as to whether a strategic transaction will be recommended by the Board of Directors, and Versartis does not intend to discuss developments with respect to the evaluation process unless a transaction is approved or disclosure becomes appropriate.
Contacts:
Joshua Brumm
COO & CFO
(650) 963-8582
jbrumm@versartis.com
